Coronado Plummets After Drug Fails in Crohn’s Trial

Massachusetts-based Coronado Bioscience’s stock fell 70 percent after trials failed to show that its drug candidate based on trichuris suis ova sent Crohn’s patients into remission better than a placebo.
Bloomberg